Yahoo Finance - WJSAM Finance Hub

Yahoo Finance

Needham Keeps Buy Rating on Carvana (CVNA) After Q3 Results

Needham Keeps Buy Rating on Carvana (CVNA) After Q...

1 week ago 8

Analysts Raise Price Targets on Expand Energy (EXE) After Q3 Results

Analysts Raise Price Targets on Expand Energy (EXE...

1 week ago 8

Analysts Stay Bullish on Micron Technology (MU)

Analysts Stay Bullish on Micron Technology (MU)

1 week ago 8

Scotiabank Keeps Sector Perform Rating on EQT After Q3 Results

Scotiabank Keeps Sector Perform Rating on EQT Afte...

1 week ago 7

Piper Sandler Raises AppLovin (APP) Price Target, Keeps Overweight Rating

Piper Sandler Raises AppLovin (APP) Price Target, ...

1 week ago 8

TD Cowen Maintains Buy on Eli Lilly (LLY) After Government Deal

TD Cowen Maintains Buy on Eli Lilly (LLY) After Go...

1 week ago 8

Taiwan Semiconductor Manufacturing Company (TSM) Board Approves Major Investment

Taiwan Semiconductor Manufacturing Company (TSM) B...

1 week ago 8

Taiwan Semiconductor Manufacturing Company (TSM) Board Approves Major Investment

Taiwan Semiconductor Manufacturing Company (TSM) B...

1 week ago 8

Despite China Issues, Nvidia (NVDA) Sees Strong Demand for Blackwell Chips

Despite China Issues, Nvidia (NVDA) Sees Strong De...

1 week ago 7

Despite China Issues, Nvidia (NVDA) Sees Strong Demand for Blackwell Chips

Despite China Issues, Nvidia (NVDA) Sees Strong De...

1 week ago 8

Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT

Stephens Initiates Twist Bioscience (TWST) With Ov...

1 week ago 9

Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT

Stephens Initiates Twist Bioscience (TWST) With Ov...

1 week ago 8

Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT

Evercore ISI Reiterates Buy Rating on Krystal Biot...

1 week ago 7

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform

RBC Capital Lifts CRISPR Therapeutics (CRSP) Targe...

1 week ago 8

RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform

RBC Capital Lifts CRISPR Therapeutics (CRSP) Targe...

1 week ago 9

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Evercore Downgrades Intellia (NTLA) Despite Strong...

1 week ago 8

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Evercore Downgrades Intellia (NTLA) Despite Strong...

1 week ago 8

Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target

Stifel Maintains Hold Rating on Vertex (VRTX), Kee...

1 week ago 6